Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis

Clin Infect Dis. 2023 Jan 6;76(1):148-151. doi: 10.1093/cid/ciac745.

Abstract

We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19) pathogenesis in a mouse model. To test relevance to human disease, we used electronic health record databases and determined that patients on dupilumab (anti-interleukin [IL]-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.

Keywords: COVID-19; dupilumab; infectious disease; type 2 immunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19*
  • Humans
  • Mice
  • Retrospective Studies

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal